Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 32 entries
Sorted by: Best Match Show Resources per page
Evaluating the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in a predominantly African American sample.

SpringerPlus

Ford ME, Wei W, Moore LA, Burshell DR, Cannady K, Mack F, Ezerioha N, Ercole K, Garrett-Mayer E.
PMID: 26266082
Springerplus. 2015 Aug 12;4:411. doi: 10.1186/s40064-015-1208-z. eCollection 2015.

PURPOSE: To evaluate the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in measuring perceptions of cancer clinical trials in a predominantly African American (AA) sample in South Carolina (SC).METHODS: Principal Component Analysis (PCA) and Cronbach's alpha estimates...

Cite
Ford ME, Wei W, Moore LA, et al. Evaluating the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in a predominantly African American sample. Springerplus. 2015;4:411doi: 10.1186/s40064-015-1208-z.
Ford, M. E., Wei, W., Moore, L. A., Burshell, D. R., Cannady, K., Mack, F., Ezerioha, N., Ercole, K., & Garrett-Mayer, E. (2015). Evaluating the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in a predominantly African American sample. SpringerPlus, 4411. https://doi.org/10.1186/s40064-015-1208-z
Ford, Marvella E, et al. "Evaluating the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in a predominantly African American sample." SpringerPlus vol. 4 (2015): 411. doi: https://doi.org/10.1186/s40064-015-1208-z
Ford ME, Wei W, Moore LA, Burshell DR, Cannady K, Mack F, Ezerioha N, Ercole K, Garrett-Mayer E. Evaluating the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in a predominantly African American sample. Springerplus. 2015 Aug 12;4:411. doi: 10.1186/s40064-015-1208-z. eCollection 2015. PMID: 26266082; PMCID: PMC4531120.
Copy Download .nbib Format: NLM
Utilizing endobronchial ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience.

Journal of bronchology & interventional pulmonology

Tanner NT, Watson P, Boylan A, Memoli JS, Pastis N, Taylor K, Garrett-Mayer E, Silvestri GA.
PMID: 23208625
J Bronchology Interv Pulmonol. 2011 Oct;18(4):317-21. doi: 10.1097/LBR.0b013e3182341b07.

BACKGROUND: : Lung cancer is the leading cause of cancer deaths worldwide, with the majority of patients presenting with advanced disease for which surgery is not an option. Recently, a number of genetic mutations have been identified that predict...

Cite
Tanner NT, Watson P, Boylan A, et al. Utilizing endobronchial ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience. J Bronchology Interv Pulmonol. 2011;18(4):317-21doi: 10.1097/LBR.0b013e3182341b07.
Tanner, N. T., Watson, P., Boylan, A., Memoli, J. S., Pastis, N., Taylor, K., Garrett-Mayer, E., & Silvestri, G. A. (2011). Utilizing endobronchial ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience. Journal of bronchology & interventional pulmonology, 18(4), 317-21. https://doi.org/10.1097/LBR.0b013e3182341b07
Tanner, Nichole T, et al. "Utilizing endobronchial ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience." Journal of bronchology & interventional pulmonology vol. 18,4 (2011): 317-21. doi: https://doi.org/10.1097/LBR.0b013e3182341b07
Tanner NT, Watson P, Boylan A, Memoli JS, Pastis N, Taylor K, Garrett-Mayer E, Silvestri GA. Utilizing endobronchial ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience. J Bronchology Interv Pulmonol. 2011 Oct;18(4):317-21. doi: 10.1097/LBR.0b013e3182341b07. PMID: 23208625.
Copy Download .nbib Format: NLM
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.

Cancer medicine

Mileham KF, Schenkel C, Bruinooge SS, Freeman-Daily J, Basu Roy U, Moore A, Smith RA, Garrett-Mayer E, Rosenthal L, Garon EB, Johnson BE, Osarogiagbon RU, Jalal S, Virani S, Weber Redman M, Silvestri GA.
PMID: 34921524
Cancer Med. 2022 Jan;11(2):530-538. doi: 10.1002/cam4.4459. Epub 2021 Dec 17.

BACKGROUND: An ASCO taskforce comprised of representatives of oncology clinicians, the American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GOMETHODS: We deployed a survey to 2374 ASCO members, targeting U.S. thoracic and general oncologists.RESULTS: We analyzed 170...

Cite
Mileham KF, Schenkel C, Bruinooge SS, et al. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. Cancer Med. 2021;11(2):530-538doi: 10.1002/cam4.4459.
Mileham, K. F., Schenkel, C., Bruinooge, S. S., Freeman-Daily, J., Basu Roy, U., Moore, A., Smith, R. A., Garrett-Mayer, E., Rosenthal, L., Garon, E. B., Johnson, B. E., Osarogiagbon, R. U., Jalal, S., Virani, S., Weber Redman, M., & Silvestri, G. A. (2022). Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. Cancer medicine, 11(2), 530-538. https://doi.org/10.1002/cam4.4459
Mileham, Kathryn F, et al. "Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists." Cancer medicine vol. 11,2 (2022): 530-538. doi: https://doi.org/10.1002/cam4.4459
Mileham KF, Schenkel C, Bruinooge SS, Freeman-Daily J, Basu Roy U, Moore A, Smith RA, Garrett-Mayer E, Rosenthal L, Garon EB, Johnson BE, Osarogiagbon RU, Jalal S, Virani S, Weber Redman M, Silvestri GA. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. Cancer Med. 2022 Jan;11(2):530-538. doi: 10.1002/cam4.4459. Epub 2021 Dec 17. PMID: 34921524; PMCID: PMC8729042.
Copy Download .nbib Format: NLM
The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies.

Clinical pharmacology and therapeutics

Rivera DR, Henk HJ, Garrett-Mayer E, Christian JB, Belli AJ, Bruinooge SS, Espirito JL, Sweetnam C, Izano MA, Natanzon Y, Robert NJ, Walker MS, Cohen AB, Boyd M, Enewold L, Hansen E, Honnold R, Kushi L, Mishra Kalyani PS, Pe Benito R, Sakoda LC, Sharon E, Tymejczyk O, Valice E, Wagner J, Lasiter L, Allen JD.
PMID: 34664259
Clin Pharmacol Ther. 2022 Jan;111(1):283-292. doi: 10.1002/cpt.2453. Epub 2021 Nov 11.

The purpose of this study was to evaluate the potential collective opportunities and challenges of transforming real-world data (RWD) to real-world evidence for clinical effectiveness by focusing on aligning analytic definitions of oncology end points. Patients treated with a...

Cite
Rivera DR, Henk HJ, Garrett-Mayer E, et al. The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. Clin Pharmacol Ther. 2021;111(1):283-292doi: 10.1002/cpt.2453.
Rivera, D. R., Henk, H. J., Garrett-Mayer, E., Christian, J. B., Belli, A. J., Bruinooge, S. S., Espirito, J. L., Sweetnam, C., Izano, M. A., Natanzon, Y., Robert, N. J., Walker, M. S., Cohen, A. B., Boyd, M., Enewold, L., Hansen, E., Honnold, R., Kushi, L., Mishra Kalyani, P. S., Pe Benito, R., Sakoda, L. C., Sharon, E., Tymejczyk, O., Valice, E., Wagner, J., Lasiter, L., & Allen, J. D. (2022). The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. Clinical pharmacology and therapeutics, 111(1), 283-292. https://doi.org/10.1002/cpt.2453
Rivera, Donna R, et al. "The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies." Clinical pharmacology and therapeutics vol. 111,1 (2022): 283-292. doi: https://doi.org/10.1002/cpt.2453
Rivera DR, Henk HJ, Garrett-Mayer E, Christian JB, Belli AJ, Bruinooge SS, Espirito JL, Sweetnam C, Izano MA, Natanzon Y, Robert NJ, Walker MS, Cohen AB, Boyd M, Enewold L, Hansen E, Honnold R, Kushi L, Mishra Kalyani PS, Pe Benito R, Sakoda LC, Sharon E, Tymejczyk O, Valice E, Wagner J, Lasiter L, Allen JD. The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. Clin Pharmacol Ther. 2022 Jan;111(1):283-292. doi: 10.1002/cpt.2453. Epub 2021 Nov 11. PMID: 34664259.
Copy Download .nbib Format: NLM
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.

Clinical cancer research : an official journal of the American Association for Cancer Research

Magnuson A, Bruinooge SS, Singh H, Wilner KD, Jalal S, Lichtman SM, Kluetz PG, Lyman GH, Klepin HD, Fleury ME, Hirsch B, Melemed A, Arnaldez FI, Basu Roy U, Schenkel C, Sherwood S, Garrett-Mayer E.
PMID: 33563633
Clin Cancer Res. 2021 May 01;27(9):2424-2429. doi: 10.1158/1078-0432.CCR-20-3868. Epub 2021 Feb 09.

PURPOSE: Performance status (PS) is one of the most common eligibility criteria. Many trials are limited to patients with high-functioning PS, resulting in important differences between trial participants and patient populations with the disease. In addition, existing PS measures...

Cite
Magnuson A, Bruinooge SS, Singh H, et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clin Cancer Res. 2021;27(9):2424-2429doi: 10.1158/1078-0432.CCR-20-3868.
Magnuson, A., Bruinooge, S. S., Singh, H., Wilner, K. D., Jalal, S., Lichtman, S. M., Kluetz, P. G., Lyman, G. H., Klepin, H. D., Fleury, M. E., Hirsch, B., Melemed, A., Arnaldez, F. I., Basu Roy, U., Schenkel, C., Sherwood, S., & Garrett-Mayer, E. (2021). Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(9), 2424-2429. https://doi.org/10.1158/1078-0432.CCR-20-3868
Magnuson, Allison, et al. "Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,9 (2021): 2424-2429. doi: https://doi.org/10.1158/1078-0432.CCR-20-3868
Magnuson A, Bruinooge SS, Singh H, Wilner KD, Jalal S, Lichtman SM, Kluetz PG, Lyman GH, Klepin HD, Fleury ME, Hirsch B, Melemed A, Arnaldez FI, Basu Roy U, Schenkel C, Sherwood S, Garrett-Mayer E. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clin Cancer Res. 2021 May 01;27(9):2424-2429. doi: 10.1158/1078-0432.CCR-20-3868. Epub 2021 Feb 09. PMID: 33563633; PMCID: PMC8102305.
Copy Download .nbib Format: NLM
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-.

Clinical cancer research : an official journal of the American Association for Cancer Research

Harvey RD, Bruinooge SS, Chen L, Garrett-Mayer E, Rhodes W, Stepanski E, Uldrick TS, Ison G, Khozin S, Rubinstein WS, Schenkel C, Miller RS, Komatsoulis GA, Schilsky RL, Kim ES.
PMID: 33563634
Clin Cancer Res. 2021 May 01;27(9):2430-2434. doi: 10.1158/1078-0432.CCR-20-3857. Epub 2021 Feb 09.

PURPOSE: Cancer clinical trials often accrue slowly or miss enrollment targets. Strict eligibility criteria are a major reason. Restrictive criteria also limit opportunities for patient participation while compromising external validity of trial results. We examined the impact of broadening...

Cite
Harvey RD, Bruinooge SS, Chen L, et al. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-. Clin Cancer Res. 2021;27(9):2430-2434doi: 10.1158/1078-0432.CCR-20-3857.
Harvey, R. D., Bruinooge, S. S., Chen, L., Garrett-Mayer, E., Rhodes, W., Stepanski, E., Uldrick, T. S., Ison, G., Khozin, S., Rubinstein, W. S., Schenkel, C., Miller, R. S., Komatsoulis, G. A., Schilsky, R. L., & Kim, E. S. (2021). Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(9), 2430-2434. https://doi.org/10.1158/1078-0432.CCR-20-3857
Harvey, R Donald, et al. "Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,9 (2021): 2430-2434. doi: https://doi.org/10.1158/1078-0432.CCR-20-3857
Harvey RD, Bruinooge SS, Chen L, Garrett-Mayer E, Rhodes W, Stepanski E, Uldrick TS, Ison G, Khozin S, Rubinstein WS, Schenkel C, Miller RS, Komatsoulis GA, Schilsky RL, Kim ES. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-. Clin Cancer Res. 2021 May 01;27(9):2430-2434. doi: 10.1158/1078-0432.CCR-20-3857. Epub 2021 Feb 09. PMID: 33563634.
Copy Download .nbib Format: NLM
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.

Clinical cancer research : an official journal of the American Association for Cancer Research

Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gönen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV.
PMID: 34312215
Clin Cancer Res. 2021 Oct 15;27(20):5472-5481. doi: 10.1158/1078-0432.CCR-21-1799. Epub 2021 Jul 26.

To address the need for clinical investigators in oncology, American Association for Cancer Research (AACR) and American Society for Clinical Oncology (ASCO) established the Methods in Clinical Cancer Research Workshop (MCCRW). The workshop's objectives were to: (i) provide training...

Cite
Von Hoff DD, Clark GM, Coltman CA, et al. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clin Cancer Res. 2021;27(20):5472-5481doi: 10.1158/1078-0432.CCR-21-1799.
Von Hoff, D. D., Clark, G. M., Coltman, C. A., Disis, M. L., Eckhardt, S. G., Ellis, L. M., Foti, M., Garrett-Mayer, E., Gönen, M., Hidalgo, M., Hilsenbeck, S. G., Littlefield, J. H., LoRusso, P. M., Lyerly, H. K., Meropol, N. J., Patel, J. D., Piantadosi, S., Post, D. A., Regan, M. M., Shyr, Y., Tempero, M. A., Tepper, J. E., Von Roenn, J., Weiner, L. M., Young, D. C., & Vu, N. V. (2021). A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(20), 5472-5481. https://doi.org/10.1158/1078-0432.CCR-21-1799
Von Hoff, Daniel D, et al. "A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,20 (2021): 5472-5481. doi: https://doi.org/10.1158/1078-0432.CCR-21-1799
Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gönen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clin Cancer Res. 2021 Oct 15;27(20):5472-5481. doi: 10.1158/1078-0432.CCR-21-1799. Epub 2021 Jul 26. PMID: 34312215; PMCID: PMC8530870.
Copy Download .nbib Format: NLM
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.

Cancer medicine

Mileham KF, Schenkel C, Bruinooge SS, Freeman-Daily J, Basu Roy U, Moore A, Smith RA, Garrett-Mayer E, Rosenthal L, Garon EB, Johnson BE, Osarogiagbon RU, Jalal S, Virani S, Weber Redman M, Silvestri GA.
PMID: 34921524
Cancer Med. 2022 Jan;11(2):530-538. doi: 10.1002/cam4.4459. Epub 2021 Dec 17.

BACKGROUND: An ASCO taskforce comprised of representatives of oncology clinicians, the American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GOMETHODS: We deployed a survey to 2374 ASCO members, targeting U.S. thoracic and general oncologists.RESULTS: We analyzed 170...

Cite
Mileham KF, Schenkel C, Bruinooge SS, et al. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. Cancer Med. 2021;11(2):530-538doi: 10.1002/cam4.4459.
Mileham, K. F., Schenkel, C., Bruinooge, S. S., Freeman-Daily, J., Basu Roy, U., Moore, A., Smith, R. A., Garrett-Mayer, E., Rosenthal, L., Garon, E. B., Johnson, B. E., Osarogiagbon, R. U., Jalal, S., Virani, S., Weber Redman, M., & Silvestri, G. A. (2022). Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. Cancer medicine, 11(2), 530-538. https://doi.org/10.1002/cam4.4459
Mileham, Kathryn F, et al. "Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists." Cancer medicine vol. 11,2 (2022): 530-538. doi: https://doi.org/10.1002/cam4.4459
Mileham KF, Schenkel C, Bruinooge SS, Freeman-Daily J, Basu Roy U, Moore A, Smith RA, Garrett-Mayer E, Rosenthal L, Garon EB, Johnson BE, Osarogiagbon RU, Jalal S, Virani S, Weber Redman M, Silvestri GA. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. Cancer Med. 2022 Jan;11(2):530-538. doi: 10.1002/cam4.4459. Epub 2021 Dec 17. PMID: 34921524.
Copy Download .nbib Format: NLM
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry.

JCO oncology practice

Mileham KF, Bruinooge SS, Aggarwal C, Patrick AL, Davis C, Mesenhowski DJ, Spira A, Clayton EJ, Waterhouse D, Moore S, Jazieh AR, Chen RC, Kaltenbaugh M, Williams JH, Gralow JR, Schilsky RL, Garrett-Mayer E.
PMID: 34694907
JCO Oncol Pract. 2021 Oct 25;OP2100394. doi: 10.1200/OP.21.00394. Epub 2021 Oct 25.

PURPOSE: People with cancer are at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. ASCO's COVID-19 registry promotes systematic data collection across US oncology practices.METHODS: Participating practices enter data on patients with SARS-CoV-2 infection in cancer...

Cite
Mileham KF, Bruinooge SS, Aggarwal C, et al. Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncol Pract. 2021;OP2100394doi: 10.1200/OP.21.00394.
Mileham, K. F., Bruinooge, S. S., Aggarwal, C., Patrick, A. L., Davis, C., Mesenhowski, D. J., Spira, A., Clayton, E. J., Waterhouse, D., Moore, S., Jazieh, A. R., Chen, R. C., Kaltenbaugh, M., Williams, J. H., Gralow, J. R., Schilsky, R. L., & Garrett-Mayer, E. (2021). Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO oncology practice, OP2100394. https://doi.org/10.1200/OP.21.00394
Mileham, Kathryn F, et al. "Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry." JCO oncology practice vol. (2021): OP2100394. doi: https://doi.org/10.1200/OP.21.00394
Mileham KF, Bruinooge SS, Aggarwal C, Patrick AL, Davis C, Mesenhowski DJ, Spira A, Clayton EJ, Waterhouse D, Moore S, Jazieh AR, Chen RC, Kaltenbaugh M, Williams JH, Gralow JR, Schilsky RL, Garrett-Mayer E. Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncol Pract. 2021 Oct 25;OP2100394. doi: 10.1200/OP.21.00394. Epub 2021 Oct 25. PMID: 34694907.
Copy Download .nbib Format: NLM
An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials.

Statistics in biopharmaceutical research

Chiuzan C, Garrett-Mayer E, Nishimura M.
PMID: 30524665
Stat Biopharm Res. 2018;10(3):185-195. doi: 10.1080/19466315.2018.1462727. Epub 2018 Apr 30.

Dose-finding in cancer clinical trials has been dominated by algorithmic designs on the principle that the highest tolerable dose is also the most effective dose. This assumption no longer applies to the biologic treatments that are characterized by different...

Cite
Chiuzan C, Garrett-Mayer E, Nishimura M. An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials. Stat Biopharm Res. 2018;10(3):185-195doi: 10.1080/19466315.2018.1462727.
Chiuzan, C., Garrett-Mayer, E., & Nishimura, M. (2018). An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials. Statistics in biopharmaceutical research, 10(3), 185-195. https://doi.org/10.1080/19466315.2018.1462727
Chiuzan, Cody, et al. "An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials." Statistics in biopharmaceutical research vol. 10,3 (2018): 185-195. doi: https://doi.org/10.1080/19466315.2018.1462727
Chiuzan C, Garrett-Mayer E, Nishimura M. An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials. Stat Biopharm Res. 2018;10(3):185-195. doi: 10.1080/19466315.2018.1462727. Epub 2018 Apr 30. PMID: 30524665; PMCID: PMC6277027.
Copy Download .nbib Format: NLM
Platelets subvert T cell immunity against cancer via GARP-TGFβ axis.

Science immunology

Rachidi S, Metelli A, Riesenberg B, Wu BX, Nelson MH, Wallace C, Paulos CM, Rubinstein MP, Garrett-Mayer E, Hennig M, Bearden DW, Yang Y, Liu B, Li Z.
PMID: 28763790
Sci Immunol. 2017 May 05;2(11). doi: 10.1126/sciimmunol.aai7911.

Cancer-associated thrombocytosis has long been linked to poor clinical outcome, but the underlying mechanism is enigmatic. We hypothesized that platelets promote malignancy and resistance to therapy by dampening host immunity. We show that genetic targeting of platelets enhances adoptive...

Cite
Rachidi S, Metelli A, Riesenberg B, et al. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol. 2017;2(11)doi: 10.1126/sciimmunol.aai7911.
Rachidi, S., Metelli, A., Riesenberg, B., Wu, B. X., Nelson, M. H., Wallace, C., Paulos, C. M., Rubinstein, M. P., Garrett-Mayer, E., Hennig, M., Bearden, D. W., Yang, Y., Liu, B., & Li, Z. (2017). Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Science immunology, 2(11), . https://doi.org/10.1126/sciimmunol.aai7911
Rachidi, Saleh, et al. "Platelets subvert T cell immunity against cancer via GARP-TGFβ axis." Science immunology vol. 2,11 (2017). doi: https://doi.org/10.1126/sciimmunol.aai7911
Rachidi S, Metelli A, Riesenberg B, Wu BX, Nelson MH, Wallace C, Paulos CM, Rubinstein MP, Garrett-Mayer E, Hennig M, Bearden DW, Yang Y, Liu B, Li Z. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol. 2017 May 05;2(11). doi: 10.1126/sciimmunol.aai7911. PMID: 28763790; PMCID: PMC5539882.
Copy Download .nbib Format: NLM
Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.

Oncoscience

Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR.
PMID: 25594059
Oncoscience. 2014 Aug 07;1(8):522-528. doi: 10.18632/oncoscience.72. eCollection 2014.

INTRODUCTION: Approximately 70% of lung adenocarcinomas express TTF-1. EGFR mutations are present in 13-15% of Western adenocarcinoma patients. This paper investigates TTF1 as a negative predictor of mutant EGFR in lung adenocarcinomas.RESULTS: In the pilot cohort (N = 301)...

Cite
Somaiah N, Fidler MJ, Garrett-Mayer E, et al. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 2014;1(8):522-528doi: 10.18632/oncoscience.72.
Somaiah, N., Fidler, M. J., Garrett-Mayer, E., Wahlquist, A., Shirai, K., Buckingham, L., Hensing, T., Bonomi, P., & Simon, G. R. (2014). Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience, 1(8), 522-528. https://doi.org/10.18632/oncoscience.72
Somaiah, Neeta, et al. "Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung." Oncoscience vol. 1,8 (2014): 522-528. doi: https://doi.org/10.18632/oncoscience.72
Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 2014 Aug 07;1(8):522-528. doi: 10.18632/oncoscience.72. eCollection 2014. PMID: 25594059; PMCID: PMC4278331.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 32 entries